About NYR

Founded: 2017
Employees: n/a
CEO: James Bonnar
WebsiteView website: www.nyrada.com

Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

Recent NYR News & Updates

New Risk • Jul 15

New minor risk - Share price stability

The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.3m free cash flow). Earnings have declined by 0.06% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (AU$2.4m revenue, or US$1.7m). Market cap is less than US$100m (AU$140.8m market cap, or US$98.4m).

Recent updates

No updates

Nyrada Inc. Stock Price

NYR Share Price Performance

NYR Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Nyrada Inc. Key Details

About NYR

Recent NYR News & Updates

Full year 2026 earnings released: AU$0.027 loss per share (vs AU$0.024 loss in FY 2025)

New minor risk - Share price stability

Here's Why We're Not Too Worried About Nyrada's (ASX:NYR) Cash Burn Situation

Recent updates

Nyrada Inc. Competitors

Clinuvel Pharmaceuticals

Racura Oncology

Tetratherix

Starpharma Holdings